Retatrutide is a peptide-based triple incretin receptor agonist that engages the GLP-1 receptor, GIP receptor, and glucagon receptor with distinct potency at each target. The compound incorporates structural modifications to optimize receptor binding and extend plasma half-life, characteristics relevant to its pharmacokinetic profile in preclinical and clinical research settings. The simultaneous engagement of all three receptors enables research into the additive and synergistic effects of incretin-based and glucagon-mediated pathways on metabolic outcomes.

Research data has established Retatrutide as among the most potent investigational compounds in clinical metabolic research studies. Its glucagon receptor component drives increased basal energy expenditure and hepatic glucose output regulation, while GLP-1 and GIP receptor activation modulate insulin secretion, appetite signaling, and gastric emptying. Studies have also examined cardiovascular outcomes, adipose tissue biology, and non-alcoholic fatty liver disease (NAFLD) models in the context of Retatrutide exposure.

This 40mg concentration is designed for research applications with extended duration or larger preclinical subject models. Retatrutide is a high-interest compound in current metabolic and endocrine research, and is frequently referenced alongside Tirzepatide and Semaglutide in comparative incretin pharmacology studies.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.